new_0222_0453|VERA|0|total_current_assets|cash_on_hand|inventories_net|net_ppe|goodwill_and_intangible|liabilities|total_current_liabilities|total_long_term_liab|total_deposits|book_value_of_equity|retained_earnings|treasury_stock|ev_revenues|ev_earnings|ev_free_cash_flow|ev_assets|ps_ratio|pe_ratio|price_to_book_value|peg_ratio|debt_equity_ratio|dividend_yield|shareholder_yield_ttm|percent_of_shares_outstanding|receivables|payables|capital_stock|return_on_invested_capital|quality_ratio_fractile|momentum_fractile|market_beta_12_month|sustainable_growth_rate|institutional_investor_ownership_percentage|average_shares_outs_diluted|total_employee_number|eps|sga_expense|shares_outstanding|repurchase_of_capital_stock|ordinary_shares_number|payout_ratio|quick_ratio|normalized_eps|stock_buyback|effective_tax_rate|return_on_equity|net_income_ttm|revenues_ttm|dividend_per_share|revenues|gross_profit|pre_tax_income|net_income|interest_income|price|total_return_price|enterprise_value|average_volume_30|one_year_return|short_interest|forward_pe_ratio|forward_pe_ratio_1y|forward_ps_ratio|forward_ps_ratio_1y|quarterly_eps_estimates|quarterly_sales_estimates|quarterly_eps_surprise|quarterly_sales_surprise|quarterly_eps_actual|quarterly_sales_actual|sales_est_0y|sales_est_1y|price_target|consensus_recommendation|price_target_num_est|eps_est_0y|eps_est_1y|r_and_d_expense|reconciled_depreciation|interest_expense_non_operating|land_and_improvements|buildings_and_improvements|other_properties|machinery_furniture_equipment|price_next_month|price_second_month
new_0222_0453|VERA|1|Vera Therapeutics Inc Total Current Assets (Quarterly) (USD)|Vera Therapeutics Inc Cash and Short Term Investments (Quarterly) (USD)|Vera Therapeutics Inc Inventories (Quarterly) (USD)|Vera Therapeutics Inc Net PP&E (Quarterly) (USD)|Vera Therapeutics Inc Goodwill and Intangibles (Quarterly) (USD)|Vera Therapeutics Inc Total Liabilities (Quarterly) (USD)|Vera Therapeutics Inc Total Current Liabilities (Quarterly) (USD)|Vera Therapeutics Inc Total Long Term Liabilities (Quarterly) (USD)|Vera Therapeutics Inc Total Deposits (Quarterly) (USD)|Vera Therapeutics Inc Book Value (Quarterly) (USD)|Vera Therapeutics Inc Retained Earnings (Quarterly) (USD)|Vera Therapeutics Inc Treasury Stock (Quarterly) (USD)|Vera Therapeutics Inc EV to Revenues|Vera Therapeutics Inc EV to Earnings|Vera Therapeutics Inc EV to Free Cash Flow|Vera Therapeutics Inc EV to Assets (Quarterly)|Vera Therapeutics Inc PS Ratio|Vera Therapeutics Inc PE Ratio|Vera Therapeutics Inc Price to Book Value|Vera Therapeutics Inc PEG Ratio|Vera Therapeutics Inc Debt to Equity Ratio|Vera Therapeutics Inc Dividend Yield|Vera Therapeutics Inc Shareholder Yield (TTM)|Vera Therapeutics Inc Percent of Shares Outstanding Short|Vera Therapeutics Inc Total Receivables (Quarterly) (USD)|Vera Therapeutics Inc Total Payables (Quarterly) (USD)|Vera Therapeutics Inc Total Capital Stock (Quarterly) (USD)|Vera Therapeutics Inc Return on Invested Capital|Vera Therapeutics Inc Quality Ratio Score|Vera Therapeutics Inc Momentum Score|Vera Therapeutics Inc Beta (1Y)|Vera Therapeutics Inc Sustainable Growth Rate (TTM)|Vera Therapeutics Inc Institutional Investor Ownership Percentage|Vera Therapeutics Inc Average Diluted Shares Outstanding (Quarterly)|Vera Therapeutics Inc Total Employees (Annual)|Vera Therapeutics Inc EPS Diluted (Quarterly) (USD)|Vera Therapeutics Inc SG&A Expense (Quarterly) (USD)|Vera Therapeutics Inc Shares Outstanding|Vera Therapeutics Inc Repurchase of Capital Stock (Quarterly) (USD)|Vera Therapeutics Inc Ordinary Shares Number (Quarterly)|Vera Therapeutics Inc Payout Ratio|Vera Therapeutics Inc Quick Ratio (Quarterly)|Vera Therapeutics Inc Normalized Diluted EPS (Quarterly) (USD)|Vera Therapeutics Inc Stock Buybacks (Quarterly) (USD)|Vera Therapeutics Inc Effective Tax Rate (TTM)|Vera Therapeutics Inc Return on Equity|Vera Therapeutics Inc Net Income (TTM) (USD)|Vera Therapeutics Inc Revenue (TTM) (USD)|Vera Therapeutics Inc Dividend Per Share (Quarterly) (USD)|Vera Therapeutics Inc Revenue (Quarterly) (USD)|Vera Therapeutics Inc Gross Profit (Quarterly) (USD)|Vera Therapeutics Inc Pre-Tax Income (Quarterly) (USD)|Vera Therapeutics Inc Net Income (Quarterly) (USD)|Vera Therapeutics Inc Net Interest Income (Quarterly) (USD)|Vera Therapeutics Inc Price (USD)|Vera Therapeutics Inc Total Return Price (USD)|Vera Therapeutics Inc Enterprise Value (USD)|Vera Therapeutics Inc 30-Day Average Daily Volume|Vera Therapeutics Inc 1 Year Price Returns (Daily)|Vera Therapeutics Inc Short Interest|Vera Therapeutics Inc PE Ratio (Forward)|Vera Therapeutics Inc PE Ratio (Forward 1y)|Vera Therapeutics Inc PS Ratio (Forward)|Vera Therapeutics Inc PS Ratio (Forward 1y)|Vera Therapeutics Inc Quarterly EPS Estimates (USD)|Vera Therapeutics Inc Quarterly Revenue Estimates (USD)|Vera Therapeutics Inc Quarterly EPS Surprise|Vera Therapeutics Inc Quarterly Revenue Surprise|Vera Therapeutics Inc Quarterly Actual EPS (USD)|Vera Therapeutics Inc Quarterly Actual Revenue (USD)|Vera Therapeutics Inc Revenue Estimates for Current Fiscal Year (USD)|Vera Therapeutics Inc Revenue Estimates for Next Fiscal Year (USD)|Vera Therapeutics Inc Price Target (USD)|Vera Therapeutics Inc Consensus Recommendation|Vera Therapeutics Inc Price Target Num Estimates|Vera Therapeutics Inc EPS Estimates for Current Fiscal Year (USD)|Vera Therapeutics Inc EPS Estimates for Next Fiscal Year (USD)|Vera Therapeutics Inc Research and Development Expense (Quarterly) (USD)|Vera Therapeutics Inc Reconciled Depreciation (Quarterly) (USD)|Vera Therapeutics Inc Non-Operating Interest Expense (Quarterly) (USD)|Vera Therapeutics Inc Land and Improvements (Quarterly) (USD)|Vera Therapeutics Inc Buildings and Improvements (Quarterly) (USD)|Vera Therapeutics Inc Other Properties (Quarterly) (USD)|Vera Therapeutics Inc Machine, Furniture & Equipment (Quarterly) (USD)||
new_0222_0453|VERA|2|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|percent_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|percent_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_beta|percent_USD_metric|percent_USD_metric|mil_figure_USD_metric|figure_whole_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_USD_metric|mil_figure_money_USD_metric|mil_figure_USD_metric|percent_USD_metric|figure_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_price|figure_money_USD_price|mil_figure_money_USD_metric|figure_USD_metric|percent_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|percent_USD_per_share_metric|percent_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_price|figure_USD_metric|figure_whole_USD_price|figure_money_USD_per_share_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric||
new_0222_0453|VERA|4|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|quarterly|quarterly|daily|quarterly|quarterly|daily|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|daily|daily|daily|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|monthly|monthly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly||
new_0222_0453|VERA|5|91|91||||91|91|91||91|91||||1.44329896907||||1.43827160494|||1.44329896907||15.4117647059|91|91|91||||||30.625|91.3333333333|91|91.3333333333|91.3333333333|22.125||91|||91.3333333333|91.4|||91|||||91.3333333333|91.3333333333|91.3333333333|1.44329896907|1.44329896907|1.44329896907|1.44242424242||15.4117647059||||||91.4285714286||||91.5|25.8571428571|25.8571428571|21.8181818182|12.6315789474|21.8181818182|||91.3333333333|91.3333333333|91.3333333333||||||
new_0222_0453|VERA|6|3|3||||3|3|3||3|3||||194||||162|||194||17|3|3|3||||||8|6|3|6|6|8||3|||6|5|||3|||||6|6|6|194|194|194|165||17||||||7||||2|7|7|11|19|11|||6|6|6||||||
new_0222_0453|VERA|7|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|daily|quarterly|daily|daily|daily|daily|quarterly|daily|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|quarterly|monthly|quarterly|yearly|quarterly|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|market_daily|market_daily|daily|market_daily|market_daily|daily|daily|daily|daily|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|daily|daily|daily|daily|daily|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly||
new_0222_0453|VERA|202003||||||||||||||||||||||||||||||||||4.0763||-0.6069|1.032||||||-0.6069|||||||||-2.474|-2.474|0.044||||||||||||||||||||||||1.439|0.108|0.024||||||
new_0222_0453|VERA|202006||||||||||||||||||||||||||||||||||4.0763||-0.8841|1.219||||||-0.8841|||||||||-3.604|-3.604|-0.062||||||||||||||||||||||||1.954|0.112|0.063||||||
new_0222_0453|VERA|202009||||||||||||||||||||||||||||||||||4.0763||-1.0941|0.652||||||-0.7467|||||||||-4.46|-4.46|-0.064||||||||||||||||||||||||1.969|0.673|0.064||||||
new_0222_0453|VERA|202012|54.261|53.654||||143.902|2.406|141.496||-89.348|-91.447||||||||||||||0.052|0.909||||||||4.0763|29|-10.518|1.136|||20.4793|||-10.1304||||-53.413|||||-42.874|-42.875|-0.013||||||||||||||||||||||||39.844|-0.642|0.015||||||
new_0222_0453|VERA|202103|51.532|49.505||||145.141|3.753|141.388||-93.316|-96.161||||-8.6012|||||||||0.0366||1.739|||||||53.0334|20.4793|12|-0.2302|1.784|21.1318||20.4793|||-0.2302||||-55.653|||||-4.714|-4.714|0.002|17.25|17.25|315.0186|||7729||||||||||||||||||2.932|0.035|||||||
new_0222_0453|VERA|202106|95.876|91.625||||5.492|3.771|1.721||92.155|-99.598||||-4.5781||||3.0616|||||0.0331||2.44|0.021||||||86.8433|10.4999|13|-0.33|2.614|21.2776||21.2776|||-0.5595|-51.176|||-55.486|||||-3.437|-3.437|0.002|13.26|13.26|190.516|59493.6667||7042|||||||||||||26|1|2|||3.235|0.05||||||18|14.74
new_0222_0453|VERA|202109|89.76|86.191||||5.69|4.042|1.648||85.477|-107.209||||-6.3374||||4.3189|||||0.5221||1.958|0.021||||||96.203|21.2655|9|-0.36|3.688|21.2776||21.2776|||-0.3429||||-58.637|||||-7.611|-7.611|0.005|17.35|17.35|282.9754|117415.3667||111089|||||||||||||26|1|2|||3.564|0.059||||||19.35|35.8
new_0222_0453|VERA|202112|||||||||||||||-10.8023||||6.6514|||||1.1405|||||||||98.6898||||||||||||||||||||||26.72|26.72|482.3465|81156.6333||242675|||||||||||||32.5|1|2||||||||||19.93|21.84
new_0222_0453|VERA|202203||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
new_0222_0453|VERA|202206||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
new_0222_0453|VERA|202209||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
new_0222_0453|VERA|202212||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||